Exane Derivatives Kodiak Sciences Inc. Transaction History

Exane Derivatives

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 22, 2022	SELL	$7.09 - $89.45 $6,685 - $84,351	-943 Closed	0 $0
Q4 2021 Jan 28, 2022	BUY	$80.85 - $128.49 $75,352 - $119,752	932 Added 8472.73%	943 $79,000
Q2 2021 Jul 28, 2021	SELL	$77.2 - $126.54 $58,672 - $96,170	-760 Reduced 98.57%	11 $1,000
Q1 2021 Apr 30, 2021	SELL	$110.45 - $164.47 $144,137 - $214,633	-1,305 Reduced 62.86%	771 $87,000
Q4 2020 Jan 27, 2021	SELL	$60.78 - $154.03 $29,842 - $75,628	-491 Reduced 19.13%	2,076 $304,000
Q3 2020 Oct 06, 2020	SELL	$45.05 - $59.27 $9,956 - $13,098	-221 Reduced 7.93%	2,567 $151,000
Q2 2020 Jul 10, 2020	SELL	$42.74 - $66.25 $26,840 - $41,605	-628 Reduced 18.38%	2,788 $150,000
Q1 2020 Apr 17, 2020	BUY	$38.18 - $73.95 $130,422 - $252,613	3,416 New	3,416 $162,000

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $450M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Exane Derivatives, based on Form 13F filings with the SEC.

Stay updated on Exane Derivatives with notifications on news.